Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STUART H COHEN

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1043290455
CMS profile
92012
Location
SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,209.35

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $1,170.00 1
Education $39.35 2

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Shionogi Inc $1,170.00 1
Janssen Pharmaceuticals, Inc $28.48 1
Merck Sharp & Dohme Corporation $10.87 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STUART H COHEN

NPI 1043290455 · CMS profile ID 92012

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043290455?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STUART H COHEN, NPI 1043290455, CMS profile ID 92012. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043290455?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). STUART H COHEN, NPI 1043290455, CMS profile ID 92012. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043290455?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
STUART H COHEN, NPI 1043290455, CMS profile ID 92012, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1043290455?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $1,209.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $28.4812/14/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788964595 CMS
Merck Sharp & Dohme Corporation $10.8711/19/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848628085 CMS
Shionogi Inc $1,170.0003/31/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851013181 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $12.70 1
PY2021 $1,209.35 3
PY2023 $9,413.35 4
PY2024 $1,236.34 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $472,103.03 26
PY2024 Principal investigator $398,042.05 23
PY2023 Principal investigator $282,460.56 40
PY2022 Principal investigator $308,819.56 68
PY2021 Principal investigator $475,681.35 25
PY2020 Principal investigator $354,189.73 100
PY2019 Principal investigator $195,701.36 93

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

100 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $132,668.93 12/24/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 No dispute reported 06/30/2026 724448361
Principal investigator 1 Gilead Sciences, Inc. $1,000.00 12/21/2020 Covered Recipient Teaching Hospital
Uc Davis Medical Center
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 742076627
Principal investigator 1 Amgen Inc. $197.85 12/09/2020 Non-covered Recipient Entity
UC DAVIS MED CTR
Not supplied No dispute reported 06/30/2026 731619403
Principal investigator 1 Merck Sharp & Dohme Corporation $2,432.00 11/06/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740819471
Principal investigator 1 Gilead Sciences, Inc. $23,404.00 11/02/2020 Covered Recipient Teaching Hospital
Uc Davis Medical Center
A Phase 1b/2a study in A Phase 1b/2a Study in Participants with Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation No dispute reported 06/30/2026 742076625
Principal investigator 1 PFIZER INC. $58.37 10/28/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742927849
Principal investigator 1 PFIZER INC. $1,109.02 10/28/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742928137
Principal investigator 1 Gilead Sciences, Inc. $3,252.00 10/12/2020 Covered Recipient Teaching Hospital
Uc Davis Medical Center
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 742076623
Principal investigator 1 PFIZER INC. $822.24 10/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742927847
Principal investigator 1 PFIZER INC. $15,620.76 10/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742928133
Principal investigator 1 Merck Sharp & Dohme Corporation $6,013.20 10/07/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740819473
Principal investigator 1 Gilead Sciences, Inc. $2,766.00 09/23/2020 Covered Recipient Teaching Hospital
Uc Davis Medical Center
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 742076621
Principal investigator 1 Merck Sharp & Dohme Corporation $8,570.80 09/18/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740819465
Principal investigator 1 Merck Sharp & Dohme Corporation $7,209.60 09/11/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740819463
Principal investigator 1 Merck Sharp & Dohme Corporation $458.52 08/25/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 740766367
Principal investigator 1 Merck Sharp & Dohme Corporation $713.97 08/25/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 740766403
Principal investigator 1 Merck Sharp & Dohme Corporation $2,027.88 08/25/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 740766405
Principal investigator 1 Merck Sharp & Dohme Corporation $2,030.68 08/25/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 740766407
Principal investigator 1 Merck Sharp & Dohme Corporation $2,030.68 08/25/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 740766409
Principal investigator 1 PFIZER INC. $1,600.00 07/09/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742944433
Principal investigator 1 Merck Sharp & Dohme Corporation $4,812.20 06/24/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740816951
Principal investigator 1 Celularity Inc. $35,496.25 06/12/2020 Covered Recipient Teaching Hospital
UC Davis Medical Center
A Phase I II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19 No dispute reported 06/30/2026 750543783
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 06/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817133
Principal investigator 1 PFIZER INC. $11,420.08 06/04/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742944431
Principal investigator 1 Merck Sharp & Dohme Corporation $2,656.40 06/03/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740816949
Principal investigator 1 Merck Sharp & Dohme Corporation $2,235.60 05/15/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740816955
Principal investigator 1 Gilead Sciences, Inc. $5,804.00 05/13/2020 Covered Recipient Teaching Hospital
Uc Davis Medical Center
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 742076619
Principal investigator 1 Merck Sharp & Dohme Corporation $8,657.40 05/13/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740816953
Principal investigator 1 Gilead Sciences, Inc. $1,726.00 04/27/2020 Covered Recipient Teaching Hospital
Uc Davis Medical Center
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 742076617
Principal investigator 1 Merck Sharp & Dohme Corporation $1,015.34 04/20/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 740766411
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817135
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817137
Principal investigator 1 Merck Sharp & Dohme Corporation $47.00 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817139
Principal investigator 1 Merck Sharp & Dohme Corporation $47.25 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817141
Principal investigator 1 Merck Sharp & Dohme Corporation $126.60 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817313
Principal investigator 1 Merck Sharp & Dohme Corporation $0.60 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817315
Principal investigator 1 Merck Sharp & Dohme Corporation $0.66 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817317
Principal investigator 1 Merck Sharp & Dohme Corporation $0.88 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817319
Principal investigator 1 Merck Sharp & Dohme Corporation $148.50 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817321
Principal investigator 1 Merck Sharp & Dohme Corporation $18.60 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817493
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817495
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817497
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817499
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817501
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817677
Principal investigator 1 Merck Sharp & Dohme Corporation $49.83 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817679
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817681
Principal investigator 1 Merck Sharp & Dohme Corporation $3.04 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817683
Principal investigator 1 Merck Sharp & Dohme Corporation $3.80 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817685
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817855
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817857
Principal investigator 1 Merck Sharp & Dohme Corporation $36.30 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817859
Principal investigator 1 Merck Sharp & Dohme Corporation $39.60 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817861
Principal investigator 1 Merck Sharp & Dohme Corporation $4.96 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740817863
Principal investigator 1 Merck Sharp & Dohme Corporation $47.00 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818033
Principal investigator 1 Merck Sharp & Dohme Corporation $47.25 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818035
Principal investigator 1 Merck Sharp & Dohme Corporation $47.25 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818037
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818039
Principal investigator 1 Merck Sharp & Dohme Corporation $5.44 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818041
Principal investigator 1 Merck Sharp & Dohme Corporation $59.40 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818215
Principal investigator 1 Merck Sharp & Dohme Corporation $6.80 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818217
Principal investigator 1 Merck Sharp & Dohme Corporation $7.70 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818219
Principal investigator 1 Merck Sharp & Dohme Corporation $0.90 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818221
Principal investigator 1 Merck Sharp & Dohme Corporation $1.04 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818223
Principal investigator 1 Merck Sharp & Dohme Corporation $1.04 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818399
Principal investigator 1 Merck Sharp & Dohme Corporation $108.90 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818401
Principal investigator 1 Merck Sharp & Dohme Corporation $11.16 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818403
Principal investigator 1 Merck Sharp & Dohme Corporation $0.16 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818405
Principal investigator 1 Merck Sharp & Dohme Corporation $0.36 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818407
Principal investigator 1 Merck Sharp & Dohme Corporation $70.50 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818589
Principal investigator 1 Merck Sharp & Dohme Corporation $72.60 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818591
Principal investigator 1 Merck Sharp & Dohme Corporation $89.10 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818593
Principal investigator 1 Merck Sharp & Dohme Corporation $96.80 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818595
Principal investigator 1 Merck Sharp & Dohme Corporation $0.60 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818597
Principal investigator 1 Merck Sharp & Dohme Corporation $0.77 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818771
Principal investigator 1 Merck Sharp & Dohme Corporation $59.40 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818773
Principal investigator 1 Merck Sharp & Dohme Corporation $62.25 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818775
Principal investigator 1 Merck Sharp & Dohme Corporation $1.35 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818777
Principal investigator 1 Merck Sharp & Dohme Corporation $110.25 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818779
Principal investigator 1 Merck Sharp & Dohme Corporation $2.34 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818955
Principal investigator 1 Merck Sharp & Dohme Corporation $83.00 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818957
Principal investigator 1 Merck Sharp & Dohme Corporation $0.40 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740819139
Principal investigator 1 Merck Sharp & Dohme Corporation $89.10 04/08/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740819141
Principal investigator 1 PFIZER INC. $655.35 03/26/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742963651
Principal investigator 1 Merck Sharp & Dohme Corporation $2,683.64 03/19/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818963
Principal investigator 1 Merck Sharp & Dohme Corporation $655.56 03/19/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740819137
Principal investigator 1 Merck Sharp & Dohme Corporation $2,140.20 03/18/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740816769
Principal investigator 1 Merck Sharp & Dohme Corporation $4,206.00 03/09/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740816945
Principal investigator 1 Merck Sharp & Dohme Corporation $14,065.60 02/26/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740816767
Principal investigator 1 Merck Sharp & Dohme Corporation $58.60 02/25/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 740766363
Principal investigator 1 Merck Sharp & Dohme Corporation $83.28 02/25/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Letermovir Versus Valganciclovir for the Prevention of Human Cytomegalovirus CMV Disease in Adult Kidney Transplant Recipients No dispute reported 06/30/2026 740766365
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,504.82 02/25/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SHP620 COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF CYTOMEGALOVIRUS (CMV) INFECTIONS THAT ARE RESISTANT OR REFRACTORY TO TREATMENT WITH GANCICLOVIR, VALGANCICLOVIR, FOSCARNET, OR CIDOFOVIR IN TRANSPLANT RECIPIENTS No dispute reported 06/30/2026 737064777
Principal investigator 1 Gilead Sciences, Inc. $1,600.00 02/24/2020 Covered Recipient Teaching Hospital
Uc Davis Medical Center
A Long Term Follow-up Registry for Subjects with Cirrhosis Who Achieve a Sustained Virologic Response to Treatment for HCV Infection in Gilead-Sponsored Trials No dispute reported 06/30/2026 742076615
Principal investigator 1 Merck Sharp & Dohme Corporation $4,025.46 02/19/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818959
Principal investigator 1 Merck Sharp & Dohme Corporation $327.78 02/19/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740819135
Principal investigator 1 PFIZER INC. $218.45 02/19/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742967457
Principal investigator 1 Merck Sharp & Dohme Corporation $218.52 02/11/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740818961
Principal investigator 1 PFIZER INC. $2,184.50 02/06/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742967491
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $21,473.98 01/14/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF SHP620 COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF CYTOMEGALOVIRUS (CMV) INFECTIONS THAT ARE RESISTANT OR REFRACTORY TO TREATMENT WITH GANCICLOVIR, VALGANCICLOVIR, FOSCARNET, OR CIDOFOVIR IN TRANSPLANT RECIPIENTS No dispute reported 06/30/2026 737064765
Principal investigator 1 Merck Sharp & Dohme Corporation $8,302.00 01/10/2020 Covered Recipient Teaching Hospital
UC DAVIS MEDICAL CENTER
A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir LET prophylaxis when extended from 100 days to 200 days post transplant in cytomegalovirus CMV seropositive recipients R of an allogenic hematopoietic stem cell transplant HSCT No dispute reported 06/30/2026 740816947